ARTICLE SUMMARY:
A companion article to "Devices for Many-Faceted Heart Failure." Acorai has developed a new sensor called SAVE for noninvasively measuring cardiac and pulmonary pressures with high accuracy. SAVE is a combination of four sensors innovatively adapted from other industries, the output of which is enabled by machine learning.
Filip Peters, the CEO and founder of Acorai, grew up in the medical device industry; his father, Tor Peters, is currently the CEO of Occlutech and has previously been a medtech CEO many times over. But Peters the younger wanted to do his own thing. He started off in finance, developing machine-learning models to trade volatility across different asset classes. Now he has returned to the fold to found heart failure company Acorai, and it turns out that his machine-learning experience outside the industry uniquely qualified him to develop a novel sensor and AI platform for noninvasively measuring pulmonary and cardiac pressures with accuracy, providing the cardiology community with a long-desired tool.
When faced with a patient experiencing shortness of breath, swelling, fatigue, and other symptoms of decompensated heart failure, cardiologists want to know the nature of the underlying dysfunction so they can administer the right treatment, but their options for measuring pulmonary and cardiac pressures with accuracy are limited. Only a small number of patients have implanted heart monitoring sensors (the CardioMEMS from Abbott or Cordella from Endotronix (Edwards Lifesciences), information from which is valuable in making treatment decisions.
